Efficacy of Pemetrexed Chemotherapy in Advanced Non-small Cell Lung Cancer with EGFR-TKI Resistence

Objective To observe the efficacy and toxicity of Pemetrexed chemotherapy in advanced non-small cell lung cancer，failed to EGFR-TKI treatment. Methods Fourteen patients were enrolled.Two patients without chemotherapy history were treated by pemetrexed combined with cisplatin;pemetrexed 500 mg/m2，intravenously，d1;DDP 25 mg/m2，d1~d3,intravenously.Twelve cases received platinum-based chemotherapy were treated with pemetrexed 500 mg/m2 alone，21 days for one cycle.All patients received at least 2 cycles of treatment. Results All 14 patients had been evaluated.Overall response rate was 35.7% (5/14)，and disease control rate was 71.4% (10/14).Median progression-free survival (PFS) and overall survival (OS) were 6.3 months and 12.5 months,respectivly. Conclusion Pemetrexed might improve clinically outcomes with well tolerance for advanced non-small cell lung cancer resisted to EGFR-TKI.